Great West Life Assurance Co. Can Sells 682 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Great West Life Assurance Co. Can decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 2.9% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 23,004 shares of the medical research company’s stock after selling 682 shares during the period. Great West Life Assurance Co. Can’s holdings in Charles River Laboratories International were worth $4,529,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Tekla Capital Management LLC boosted its stake in Charles River Laboratories International by 51.7% during the third quarter. Tekla Capital Management LLC now owns 72,675 shares of the medical research company’s stock valued at $14,302,000 after buying an additional 24,781 shares during the period. Financial Counselors Inc. raised its position in Charles River Laboratories International by 12.2% during the third quarter. Financial Counselors Inc. now owns 27,536 shares of the medical research company’s stock valued at $5,419,000 after purchasing an additional 2,986 shares in the last quarter. Reinhart Partners Inc. purchased a new stake in Charles River Laboratories International during the third quarter valued at about $9,205,000. Mitchell & Pahl Private Wealth LLC raised its position in Charles River Laboratories International by 5.7% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 2,058 shares of the medical research company’s stock valued at $405,000 after purchasing an additional 111 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Charles River Laboratories International by 13.8% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 35,553 shares of the medical research company’s stock valued at $6,997,000 after purchasing an additional 4,310 shares in the last quarter. Institutional investors own 97.80% of the company’s stock.

Charles River Laboratories International Stock Up 4.1 %

Shares of NYSE:CRL opened at $243.17 on Monday. Charles River Laboratories International, Inc. has a 1 year low of $181.36 and a 1 year high of $349.84. The company has a market cap of $12.37 billion, a PE ratio of 28.64, a P/E/G ratio of 1.53 and a beta of 1.29. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.40 and a quick ratio of 1.14. The stock’s 50-day moving average is $226.53 and its 200 day moving average is $218.44.

Charles River Laboratories International (NYSE:CRLGet Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The medical research company reported $2.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.12. Charles River Laboratories International had a return on equity of 20.93% and a net margin of 11.54%. The company had revenue of $989.16 million for the quarter, compared to the consensus estimate of $978.65 million. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.89 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 6,409 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $224.25, for a total transaction of $1,437,218.25. Following the sale, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at approximately $4,537,026. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 6,409 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, December 1st. The stock was sold at an average price of $224.25, for a total transaction of $1,437,218.25. Following the sale, the executive vice president now directly owns 20,232 shares of the company’s stock, valued at approximately $4,537,026. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Michael Gunnar Knell sold 855 shares of Charles River Laboratories International stock in a transaction that occurred on Wednesday, November 16th. The shares were sold at an average price of $248.59, for a total value of $212,544.45. Following the sale, the chief accounting officer now directly owns 6,438 shares in the company, valued at $1,600,422.42. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,077 shares of company stock valued at $2,334,821. 1.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Credit Suisse Group lowered their price target on Charles River Laboratories International from $285.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, November 3rd. William Blair restated an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, November 2nd. StockNews.com assumed coverage on Charles River Laboratories International in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Robert W. Baird raised their price target on Charles River Laboratories International from $275.00 to $285.00 and gave the company an “outperform” rating in a research report on Wednesday, January 11th. Finally, JPMorgan Chase & Co. decreased their price objective on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating on the stock in a report on Thursday, November 3rd. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $297.38.

Charles River Laboratories International Company Profile

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Read More

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.